AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer.
Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in advancing novel therapeutics from discovery and translational research through global clinical development, regulatory interactions and commercialization planning.
"We are delighted to welcome Cameron to AN2 Therapeutics," said Eric Easom, Co-Founder, President and Chief Executive Officer of AN2 Therapeutics. "Cameron's extensive experience building and leading clinical organizations, advancing innovative therapies through development, and engaging with regulators, investigators and patients will be invaluable as we continue to advance our pipeline. His scientific rigor, patient-centric mindset and proven leadership across both emerging biotechnology companies and large pharmaceutical organizations make him an outstanding addition to our executive team.”
